BioMedTech
-
Lung cancer boost as Biofidelity now takes ‘supertest’ to labs worldwide
Biofidelity, a genomic technology company with UK headquarters at Cambridge Science Park and a US flagship in North Carolina, is enabling... Read More
-
Evonetix and Analog Devices Inc to progress revolutionary gene synthesis platform
It’s a hybrid tech marriage made in heaven: Evonetix, a Cambridge biotech pioneer and Analog Devices Inc (ADI) – a US-based world leader in... Read More
-
New world-class functional genomics lab for Cambridge
The Milner Therapeutics Institute in Cambridge is to house a new, world-class functional genomics laboratory in partnership with AstraZeneca and the... Read More
-
Exonate makes progress in $8.3bn market
Cambridge biotech Exonate says its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a phase Ib/IIa study. It reveals... Read More
-
$3bn sales potential for drug Sosei Heptares wants back from GSK
Sosei Heptares, which has R & D facilities in Cambridge, says a drug it intends to regain from GSK has potential global peak sales of more than $... Read More
-
Data driven clinical practice boosted by CMR Surgical and Ledidi
CMR Surgical in Cambridge has joined forces with Norwegian software business Ledidi to promote data-driven clinical practice and improve care quality... Read More
-
Constructive Bio scales to new Cambridge headquarters
Constructive Bio, a Cambridge biotech that rewrites genomes to create biomolecules that were previously unimaginable, has scaled to a new HQ in the... Read More
-
US $50m helps Sanger-inspired startup to create transformative medicine suite
Genetics startup Quotient Therapeutics has roared out of stealth on both sides of the Atlantic on the wings of intellectual input from Wellcome... Read More
-
AstraZeneca launches new HealthTech business to spawn nextgen medicines
Cambridge-headquartered Big Biotech AstraZeneca has launched a global health-tech business, Evinova, to accelerate innovation across the life... Read More
-
Astex and AstraZeneca hail latest triumph with new breast cancer drug
A long-standing alliance between Cambridge life science duo Astex Pharmaceuticals and AstraZeneca has borne fruit – thanks to the sale of a new... Read More
-
Ex Sanger chief leads new Cambridge medicines powerhouse T-Therapeutics in $59m Series A
Cambridge University spin-out T-Therapeutics has raised $59 million in a Series A financing led by Sofinnova Partners, F-Prime Capital, Digitalis... Read More
-
Astex director goes under the hood of key genetics approach
Harpreet Saini, Senior Director of Informatics at Astex Pharmaceuticals in Cambridge, is a keynote speaker at the Bio-IT World summit in London later... Read More
-
Cambridge nanomedicine company raises $25m growth capital
Cambridge company ViaNautis Bio, a groundbreaking nanomedicine company at the forefront of genetic therapies and based at Babraham Research Campus,... Read More
-
Mission distinctly possible! Cambridge moves closer to new Parkinson’s drug
Mission Therapeutics is on the cusp of an exciting breakthrough in the global fight against Parkinson’s Disease thanks to a fruitful alliance with... Read More
-
Illumina steps up shipments of new sequencer as Q3 sales fall flat
US genomics giant Illumina, whose EMEA HQ is in Cambridge, reports flat revenue of $1.12 billion for the third quarter of 2023. That figure is one... Read More
-
AstraZeneca earmarks $2bn+ for China solution targeting type 2 diabetes and obesity
AstraZeneca saw its UK share price head sharply northwards after posting excellent results for Q3 and the first nine months of 2023 – lifting total... Read More
-
bit.bio fast-tracks progress towards the clinic
bit.bio, a Cambridge company coding human cells for novel cures, has unveiled its cell therapy pipeline and declared its lead cell therapy candidate... Read More
-
AstraZeneca continues to fight prostate cancer in Kenya
In a significant boost to prostate cancer diagnosis in Kenya, AstraZeneca has donated a cutting-edge ultrasound biopsy machine to Kenyatta National... Read More
-
Cyted test could save millions after it clears endoscopy backlogs and cuts costs in NHS pilot
Diagnostic technology from Cambridge health company Cyted could reduce NHS endoscopy waiting lists by over 75 per cent, an independent evaluation of... Read More
-
Huge support as Danaher pays Cambridge record $5.7bn for Abcam
Abcam founder Jonathan Milner delivered a withering parting shot to the management and board after a $5.7 billion sale to US giant Danaher... Read More